Bevacizumab zirconium Zr-89

Generic Name
Bevacizumab zirconium Zr-89
Brand Names
-
Drug Type
Biotech
Chemical Formula
-
CAS Number
-
Unique Ingredient Identifier
B552L536ZL
Background

Bevacizumab zirconium Zr-89 is under investigation in clinical trial NCT01338090 (89Zr-bevacizumab PET Imaging in Patients With Neuroendocrine Tumors).

Associated Conditions
-
Associated Therapies
-
Clinical Trials
Related News

89Zr-Bevacizumab PET/CT Imaging in NF2 Patients

First Posted Date
2023-01-17
Last Posted Date
2024-03-20
Lead Sponsor
Leiden University Medical Center
Target Recruit Count
15
Registration Number
NCT05685836
Locations
🇳🇱

Leiden University Medical Center, Leiden, Zuid-Holland, Netherlands

Pilot Study of Zirconium-89 Bevacizumab Positron Emission Tomography for Imaging Angiogenesis in Patients With Inflammatory Breast Carcinoma Receiving Preoperative Chemotherapy

First Posted Date
2013-07-10
Last Posted Date
2019-12-12
Lead Sponsor
Dana-Farber Cancer Institute
Target Recruit Count
2
Registration Number
NCT01894451
Locations
🇺🇸

Brigham and Womens Hospital, Boston, Massachusetts, United States

🇺🇸

Dana Farber Cancer Institute, Boston, Massachusetts, United States

89Zr-bevacizumab PET Scan in Patients With Relapsing Multiple Myeloma

Not Applicable
Conditions
Multiple Myeloma
Interventions
Drug: 89Zr-bevacizumab
First Posted Date
2013-05-21
Last Posted Date
2013-05-21
Lead Sponsor
University Medical Center Groningen
Target Recruit Count
20
Registration Number
NCT01859234
Locations
🇳🇱

UMCG, Groningen, Netherlands

89Zr-bevacizumab PET Imaging in Patients With Neuroendocrine Tumors

First Posted Date
2011-04-19
Last Posted Date
2012-04-03
Lead Sponsor
University Medical Center Groningen
Target Recruit Count
14
Registration Number
NCT01338090
Locations
🇳🇱

University Medical Center Groningen, Groningen, Netherlands

© Copyright 2024. All Rights Reserved by MedPath
HomeTerms & ConditionsPrivacy Policy